293 related articles for article (PubMed ID: 34949695)
1. Leptomeningeal disease and brain control after postoperative stereotactic radiosurgery with or without immunotherapy for resected brain metastases.
Minniti G; Lanzetta G; Capone L; Giraffa M; Russo I; Cicone F; Bozzao A; Alongi F; Nicosia L; Fineschi G; Marchetti L; Tufo T; Bianciardi F; Esposito V; Gentile P; Paolini S
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949695
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of postoperative stereotactic radiosurgery to the resection cavity versus stereotactic radiosurgery alone for melanoma brain metastases.
Minniti G; Paolini S; D'Andrea G; Lanzetta G; Cicone F; Confaloni V; Bozzao A; Esposito V; Osti M
J Neurooncol; 2017 May; 132(3):455-462. PubMed ID: 28260130
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of multi-fraction stereotactic radiosurgery for surgically resected or intact large brain metastases from non-small-cell lung cancer (NSCLC).
Minniti G; Scaringi C; Lanzetta G; Anzellini D; Bianciardi F; Tolu B; Morace R; Romano A; Osti M; Gentile P; Paolini S
Lung Cancer; 2019 Jun; 132():119-125. PubMed ID: 31097084
[TBL] [Abstract][Full Text] [Related]
4. Risk of leptomeningeal disease in patients treated with stereotactic radiosurgery targeting the postoperative resection cavity for brain metastases.
Atalar B; Modlin LA; Choi CY; Adler JR; Gibbs IC; Chang SD; Harsh GR; Li G; Nagpal S; Hanlon A; Soltys SG
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):713-8. PubMed ID: 24054875
[TBL] [Abstract][Full Text] [Related]
5. Surgical Resection of Brain Metastases and the Risk of Leptomeningeal Recurrence in Patients Treated With Stereotactic Radiosurgery.
Johnson MD; Avkshtol V; Baschnagel AM; Meyer K; Ye H; Grills IS; Chen PY; Maitz A; Olson RE; Pieper DR; Krauss DJ
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):537-43. PubMed ID: 26867883
[TBL] [Abstract][Full Text] [Related]
6. Intracranial control and radiographic changes with adjuvant radiation therapy for resected brain metastases: whole brain radiotherapy versus stereotactic radiosurgery alone.
Patel KR; Prabhu RS; Kandula S; Oliver DE; Kim S; Hadjipanayis C; Olson JJ; Oyesiku N; Curran WJ; Khan MK; Shu HK; Crocker I
J Neurooncol; 2014 Dec; 120(3):657-63. PubMed ID: 25189789
[TBL] [Abstract][Full Text] [Related]
7. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.
Singh C; Qian JM; Yu JB; Chiang VL
J Neurosurg; 2019 Feb; 132(2):512-517. PubMed ID: 30771783
[TBL] [Abstract][Full Text] [Related]
8. Surgical resection and postoperative radiosurgery versus staged radiosurgery for large brain metastases.
Dohm AE; Hughes R; Wheless W; Lecompte M; Lanier C; Ruiz J; Watabe K; Xing F; Su J; Cramer C; Laxton A; Tatter S; Chan MD
J Neurooncol; 2018 Dec; 140(3):749-756. PubMed ID: 30367382
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Radiosurgery for Resected Brain Metastases: Single-Institutional Experience of Over 500 Cavities.
Shi S; Sandhu N; Jin MC; Wang E; Jaoude JA; Schofield K; Zhang C; Liu E; Gibbs IC; Hancock SL; Chang SD; Li G; Hayden-Gephart M; Adler JR; Soltys SG; Pollom EL
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(4):764-771. PubMed ID: 31785338
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
[TBL] [Abstract][Full Text] [Related]
11. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.
Angelov L; Mohammadi AM; Bennett EE; Abbassy M; Elson P; Chao ST; Montgomery JS; Habboub G; Vogelbaum MA; Suh JH; Murphy ES; Ahluwalia MS; Nagel SJ; Barnett GH
J Neurosurg; 2018 Aug; 129(2):366-382. PubMed ID: 28937324
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic radiosurgery for focal leptomeningeal disease in patients with brain metastases.
Wolf A; Donahue B; Silverman JS; Chachoua A; Lee JK; Kondziolka D
J Neurooncol; 2017 Aug; 134(1):139-143. PubMed ID: 28536993
[TBL] [Abstract][Full Text] [Related]
13. Comparing pre-operative stereotactic radiosurgery (SRS) to post-operative whole brain radiation therapy (WBRT) for resectable brain metastases: a multi-institutional analysis.
Patel KR; Burri SH; Boselli D; Symanowski JT; Asher AL; Sumrall A; Fraser RW; Press RH; Zhong J; Cassidy RJ; Olson JJ; Curran WJ; Shu HG; Crocker IR; Prabhu RS
J Neurooncol; 2017 Feb; 131(3):611-618. PubMed ID: 28000105
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for leptomeningeal carcinomatosis in patients with brain metastases who have previously undergone stereotactic radiosurgery.
Huang AJ; Huang KE; Page BR; Ayala-Peacock DN; Lucas JT; Lesser GJ; Laxton AW; Tatter SB; Chan MD
J Neurooncol; 2014 Oct; 120(1):163-9. PubMed ID: 25048529
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis.
Ojerholm E; Lee JY; Thawani JP; Miller D; O'Rourke DM; Dorsey JF; Geiger GA; Nagda S; Kolker JD; Lustig RA; Alonso-Basanta M
J Neurosurg; 2014 Dec; 121 Suppl():75-83. PubMed ID: 25434940
[TBL] [Abstract][Full Text] [Related]
16. SAFESTEREO: phase II randomized trial to compare stereotactic radiosurgery with fractionated stereotactic radiosurgery for brain metastases.
Crouzen JA; Petoukhova AL; Broekman MLD; Fiocco M; Fisscher UJ; Franssen JH; Gadellaa-van Hooijdonk CGM; Kerkhof M; Kiderlen M; Mast ME; van Rij CM; Nandoe Tewarie R; van de Sande MAE; van der Toorn PPG; Vlasman R; Vos MJ; van der Voort van Zyp NCMG; Wiggenraad RGJ; Wiltink LM; Zindler JD
BMC Cancer; 2023 Mar; 23(1):273. PubMed ID: 36964529
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated Stereotactic Radiation Therapy to the Resection Bed for Intracranial Metastases.
Keller A; Doré M; Cebula H; Thillays F; Proust F; Darié I; Martin SA; Delpon G; Lefebvre F; Noël G; Antoni D
Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1179-1189. PubMed ID: 28974415
[TBL] [Abstract][Full Text] [Related]
18. A multi-institutional analysis of presentation and outcomes for leptomeningeal disease recurrence after surgical resection and radiosurgery for brain metastases.
Prabhu RS; Turner BE; Asher AL; Marcrom SR; Fiveash JB; Foreman PM; Press RH; Patel KR; Curran WJ; Breen WG; Brown PD; Jethwa KR; Grills IS; Arden JD; Foster LM; Manning MA; Stern JD; Soltys SG; Burri SH
Neuro Oncol; 2019 Aug; 21(8):1049-1059. PubMed ID: 30828727
[TBL] [Abstract][Full Text] [Related]
19. Comparison of preoperative versus postoperative treatment dosimetry plans of single-fraction stereotactic radiosurgery for surgically resected brain metastases.
Cheok SK; Yu C; Feng JJ; Briggs RG; Chow F; Hwang L; Ye JC; Attenello FJ; Tran D; Chang E; Zada G
Neurosurg Focus; 2023 Aug; 55(2):E9. PubMed ID: 37527673
[TBL] [Abstract][Full Text] [Related]
20. Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases.
Bachmann N; Leiser D; Ermis E; Vulcu S; Schucht P; Raabe A; Aebersold DM; Herrmann E
Radiat Oncol; 2019 Mar; 14(1):45. PubMed ID: 30871597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
